Lantern Pharma Launches 'Webinar Wednesdays' Series on Oncology Drug Development

Lantern Pharma Inc. has announced the launch of "Webinar Wednesdays," a new webinar series spotlighting key areas of interest in oncology drug development. Leveraging insights from leading physicians, scientists, and Lantern collaborators, each session will delve into topics related to the company's targeted cancer therapies and AI-driven drug development initiatives. The inaugural webinar, held on April 24, featured Dr. Joseph Treat presenting on LP-300, a promising therapeutic for non-small cell lung cancer in never-smokers. In the upcoming session, Dr. Igor Astsaturov will discuss his approach to treating pancreatic cancer and other solid tumors, including Lantern's synthetically lethal drug candidate, LP-184, and its role in the evolving landscape of biomarker-driven cancer treatments. These webinars offer an opportunity for in-depth exploration of Lantern's research, collaborations, clinical trials, and future goals.